Chris Kittredge

Chris Kittredge is a Partner in the Boston office. He develops corporate positioning, issues preparedeness and investor relations programs and has extensive experience in advising clients on M&A, IPO, crisis, shareholder activism and other special situations.

Recent engagements include advising Akili Interactive on its SPAC transaction with Social Capital Suvretta; Alnylam on its management succession announcement; Alexion on activism from Elliott Management and its sale to Astrazeneca; 23andMe on its SPAC transaction with VGAC; the IPO of Cue Health, bluebird bio on its separation announcement; and Carbonite on its sale to OpenText.

Chris has also counseled clients on high-profile engagements, including Moderna on its IPO; NiSource on a settlement with the DOJ related to explosions in the Merrimack Valley of New England and subsequent sale of Columbia Gas of Massachusetts; multiple private schools related to investigations of alleged historic faculty misconduct; former Goldman Sachs trader Fabrice Tourre in his legal defense against civil securities fraud; and Paul, Weiss Rifkind, Wharton & Garrison LLP in connection with an independent report to the National Football League concerning issues of player misconduct at the Miami Dolphins.

Chris has also led corporate positioning support engagements for Canapi Ventures, Blackstone Life Sciences, the global law firm Linklaters LLP, investment firm The Rohatyn Group and investment bank Leerink Partners, among others.

Chris began his career at The Caraway Group, Inc., a public affairs agency in Washington, D.C. He graduated from Ohio Wesleyan University with a B.A. in Economics Management and Sociology.